ArticleJournal of microbiology and biotechnology2025
Effects of Chronic Administration of a Standardized Rice Bran Supplement on Sleep Architecture and Profiles in Mice: A Comparative Study with a Hypnotic Drug Zolpidem.
Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the effects of chronic administration of rice bran supplement (RBS) on sleep and to compare these effects with those of the hypnotic drug zolpidem (ZPD). During the three-week treatment period, ZPD initially reduced sleep latency, but that reduction effect of sleep latency gradually diminished over time and significantly decreased non-rapid eye movement sleep (NREMS). In contrast, RBS reduced sleep latency and increased NREMS on the first day, and these effects persisted throughout the treatment period. Additionally, RBS altered the time course of NREMS, which persisted until day 21. Importantly, while RBS did not affect delta activity during the treatment period, the ZPD group experienced a decrease in delta activity on the first day, which recovered by day 21. Our findings suggest that RBS does not induce tolerance during chronic administration and does not alter sleep architecture upon discontinuation, indicating that it could be utilized as a natural sleep aid suitable for long-term consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.